Repeat Imaging in One Year
For a 9 mm hyperdense left renal lesion without enhancement on CT urogram suggesting a hemorrhagic or proteinaceous cyst, repeat imaging in one year is the appropriate management—urology referral is not necessary at this time.
Rationale Based on Imaging Characteristics
The key finding here is lack of enhancement on CT urogram. This is the critical discriminator between benign cystic lesions and malignancy:
- Homogeneous high T1 signal intensity lesions with smooth borders and lesion-to-renal parenchyma signal intensity ratio >1.6 predict benign cysts with accuracies of 73.6% to 79.9% 1
- Hyperdense renal masses (measuring 30-60 HU greater than adjacent parenchyma) that do not enhance are characteristic of hemorrhagic or proteinaceous cysts 2, 3, 4
- The 9 mm size is small and falls well within the range where benign cystic lesions predominate
Why Not Refer to Urology Now?
The absence of enhancement effectively rules out renal cell carcinoma (RCC) as the primary concern. The 2025 EAU guidelines emphasize that imaging can reliably distinguish complex cystic lesions using the Bosniak classification, with active surveillance recommended as an alternative to primary surgery for Bosniak III cysts since only 51% are malignant and have low malignant potential 5. Your lesion, being hyperdense without enhancement, doesn't even meet criteria for Bosniak III.
Key Imaging Principles:
- Enhancement threshold of >15% on MRI or >10-20 HU on CT is required to diagnose solid tumors 1
- Hyperdense cysts without enhancement are benign in the vast majority of cases 2, 3
- The bilateral benign-appearing cysts in your patient further support a benign cystic process
Recommended Follow-Up Strategy
Repeat imaging at 12 months with either:
- CT with contrast (preferred if renal function permits) to confirm stability and continued lack of enhancement
- MRI with contrast if there are concerns about radiation or contrast nephropathy—MRI has higher specificity (68.1% vs 27.7% for CT) for diagnosing RCC while maintaining equivalent sensitivity 1
What to Look For on Follow-Up:
- Stability in size (growth would be concerning)
- Continued absence of enhancement (any new enhancement warrants biopsy or urology referral)
- No development of solid components, thick septations, or nodularity
When to Refer to Urology
Refer if follow-up imaging demonstrates:
- Any enhancement (>10-20 HU increase on CT or >15% on MRI)
- Interval growth of the lesion
- Development of solid components or irregular features
- Patient develops symptoms (hematuria, flank pain, palpable mass)
Important Caveats
While the ACR guidelines note that nondiagnostic findings cannot be considered evidence of benignity 1, your case has diagnostic findings: a hyperdense lesion without enhancement. This is distinctly different from an indeterminate lesion with equivocal enhancement.
Renal mass biopsy is not indicated for clearly benign-appearing cystic lesions without enhancement 1. Biopsy is reserved for solid enhancing masses where imaging cannot distinguish benign from malignant etiologies, or when there are features suggestive of fat-poor angiomyolipoma.
The presence of bilateral benign-appearing renal cysts and vascular calcifications in your patient suggests a benign cystic disease process rather than malignancy, further supporting conservative management with surveillance.